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BRCA1 plays a pivotal role in the repair of DNA damage, especially following chemotherapy and ionising radiation. We were
interested in the regulation of BRCA1 expression in acute myeloid leukaemia (AML), in particular in therapy-related forms (t-AML).
Using real-time PCR and Western blot, we found that BRCA1 mRNA was expressed at barely detectable levels by normal peripheral
blood granulocytes, monocytes and lymphocytes, whereas control BM-mononuclear cells and selected CD34þ progenitor cells
displayed significantly higher BRCA1 expression (P¼0.0003). Acute myeloid leukaemia samples showed heterogeneous BRCA1
mRNA levels, which were lower than those of normal bone marrows (P¼0.0001). We found a high frequency of hypermethylation
of the BRCA1 promoter region in AML (51/133 samples, 38%), in particular in patients with karyotypic aberrations (P¼0.026), and in
t-AML, as compared to de novo AML (76 vs 31%, P¼0.0002). Examining eight primary tumour samples from hypermethylated t-AML
patients, BRCA1 was hypermethylated in three of four breast cancer samples, whereas it was unmethylated in the other four
tumours. BRCA1 hypermethylation correlated to reduced BRCA1 mRNA (P¼0.0004), and to increased DNA methyltransferase
DNMT3A (P¼0.003) expression. Our data show that reduced BRCA1 expression owing to promoter hypermethylation is frequent
in t-AML and that this could contribute to secondary leukaemogenesis.
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BRCA1 is a 1863 amino-acid protein, particularly expressed by
actively dividing cells, important for regulation of cell prolifera-
tion, DNA repair, the maintenance of genomic integrity and
induction of apoptosis in damaged cells (Venkitaraman, 2002). In
particular, BRCA1 participates in homologous recombination and
nonhomologous end-joining, facilitating repair of double-strand
DNA breakages, which frequently occur following antiblastic
treatment. BRCA1 is widely expressed by proliferating tissues
pointing to a general role in maintaining genomic integrity
(Blackshear et al, 1998). Mutations of BRCA1 occur in at least 10%
of inherited breast cancers, but are very rare in sporadic breast
cancer. BRCA1 expression is repressed through promoter hyper-
methylation in 11–31% of breast, 5–15% of ovarian cancer and
about 60% of pancreatic ductal carcinoma (Catteau and Morris,
2002; Peng et al, 2006). The biologic effects of the loss of BRCA1
gene function caused by promoter hypermethylation and by
coding-region mutations in breast and ovarian cancer produce
similar microarray patterns of reduced gene expression (Hedenfalk
et al, 2001).
We were interested in BRCA1 expression in normal bone
marrow (BM) and peripheral blood (PB) haematopoietic cells, and
in AMLs. In particular, we studied BRCA1 regulation by promoter
hypermethylation in therapy-related AML (t-AML), as drugs and
radiation have been shown to induce DNA hypermethylation, and
BRCA1 has an important role in the repair process of DNA
damage, induced by these agents (Issa et al, 1996; Kennedy et al,
2004; Pogribny et al, 2004).
PATIENTS AND METHODS
Our analysis included 133 AML patients (60 females and 73 males,
median age 62 years, range 16–85 years), diagnosed between April
1995 and October 2004. The diagnosis of AML was established
according to morphology and immunophenotype.
Twenty-one patients had a leukaemia secondary to treatment for
a previous malignancy (eight breast cancer, two Hodgkin’s
lymphoma, three non-Hodgkin’s lymphoma, two multiple myeloma,
one Waldenstrom’s macroglobulinemia, one essential thrombo-
cytemia, one prostate, two thyroid and one lung cancer) and were
defined ‘therapy-related AML’ (Table 1). Karyotype was available
for 92 patients, 15 of whom had a t-AML. Thirty-eight patients had
a normal karyotype, 24 a balanced translocation and 30 other
chromosomal aberrations. Controls included normal BM and PB
samples. Informed consent was obtained from all patients,
according to institutional guidelines.
RNA and protein expression
We studied BRCA1 mRNA expression by real-time PCR in
BM samples of 56 AML patients and in several normal blood Received 4 May 2006; revised 22 August 2006; accepted 23 August 2006
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scell subsets. Mononuclear progenitor cells were separated from 16
normal BM aspirates using Ficoll density centrifugation and
CD34þ cells were isolated using immunomagnetic beads (n¼8,
Miltenyi Biotec GmbH, Bergisch Gladbach, Germany). Mature
granulocytes were separated from the PB of four normal donors,
following 2-h of incubation with Voluven (Fresenius KABI, Italy),
and density-gradient centrifugation on Lympholyte-H (Cederlane,
Ontario, Canada). Peripheral blood-monocytes (n¼7) were
separated from lymphocytes (n¼9) following 1-h adherence in
culture dishes.
Mononuclear cells (MNC) were separated from the BM of AML
patients at the time of initial diagnosis, using Ficoll and were
frozen in RLT Buffer (Qiagen GmbH, Hilden, Germany) for RNA
extraction and at  801C as pellets for DNA and protein extraction.
The haematopoietic cell lines HL-60, TF-1, KG1 and the
lymphoblastic cell lines Raji and Jurkat (all from LGC-ATCC,
Middlesex, UK) were also examined.
RNA was extracted using the RNeasy kit (Qiagen) and was
reverse transcribed using random hexamers as reaction primers.
Quantitative assessments of cDNA amplification for BRCA1
(Esteller et al, 2000), DNMT1, 3A, 3B and the internal reference
genes 18S and cyclin D2 for DNMT were performed by a
fluorescence-based real-time detection method (Biorad,
Munchen, Germany) and the iQt SYBR Green SuperMIX
(Biorad). Oligonucleotides used are described in Table 2.
Polymerase chain reaction consisted of 3min at 951C, followed
by 30 cycles at 951C for 15s and 601C for 1min. To assure
the amplicon specificity of each primer set, the PCR products
were then subjected to a melting curve analysis. For each PCR,
a standard curve was produced, using four consecutive 1:10
dilutions of a positive sample. All samples were run in triplicate.
The relative amount of mRNA in the samples was calculated
using the following calculation:
Relativeamountof mRNA :
2 DCt 10000ðDCt ¼ Ctspecific
gene   CtReferencegeneÞ:
BRCA1 protein expression was analysed by Western blot in 19
AML patients. Proteins were detected by hybridisation with the
primary mouse monoclonal anti-BRCA1 (D-9, sc-6954, Santa Cruz
Biotechnology, Santa Cruz, CA, USA) and anti-b-tubulin anti-
bodies (D-10, sc-5274, Santa Cruz Biotechnology) in 5% bovine
serum albumin/1 TBST/0.1% sodium azide, overnight at 41C and
1h at room temperature, respectively.
Analysis of BRCA1 methylation
We then studied regulation of BRCA1 promoter hypermethylation
in the BM of 133 AML patients, at the time of diagnosis.
The PB of 25 donors (median age 47 years, range 18 –60 years)
and 15 normal BMs (median age 39 years, range 23–75 years) were
analysed as control. The cell lines HL-60, TF-1, KG1, Raji and
Jurkat (LGC-ATCC) were also studied. Patients’ and controls’ DNA
was extracted using DNAzol (Gibco BRL, Eggenstein, Germany),
following the manufacturers’ instructions. DNA samples extracted
from paraffin-embedded tissue from the primary tumour were
available for eight patients (four breast cancers, two lymphopro-
liferative diseases and two lung cancers). Six of these patients had a
t-AML, two patients received surgery alone for the primary
tumour.
DNA methylation pattern in the CpG island of the BRCA1
promoter was determined by methylation-specific PCR (MSP),
Table 1 BRCA1 methylation status and patients’ characteristics
Methylated Unmethylated
nn (%) n (%) P
Age (years) o60 (60) 20 (33) 40 (67) 0.5
461 (73) 31 (42.5) 42 (57.5)
Gender Females (60) 25 (42) 35 (58) 0.6
Males (73) 26 (36) 47 (64)
Karyotype (n¼92) Normal (38) 8 (21) 30 (79) 0.026
Simple Transl. (24) 9(37.5) 15 (62.5)
Complex (30) 15 (50) 15 (50)
Trilineage dysplasia No (90) 30 (33) 60 (67) 0.1
Yes (39) 19 (49) 20 (51)
Blast cell% (n¼112) o50 (39) 17 (43.5) 22 (56.5) 0.3
450 (73) 24 (33) 49 (67)
WBC counts (n¼127) o30 10
9l
 1 (96) 34 (35) 62 (65) 0.4
430 10
9l
 1 (31) 14 (45) 17 (55)
Type De novo (112) 35 (31) 77 (69) 0.0002
a
Therapy-related (21) 16 (76) 5 (24)
Primary tumour Breast (8) 7 (87.5) 1 (12.5)
Lymphoproliferative (8) 6 (75) 2 (25)
Thyroid (2) 2 (100) 0 (0)
Other (3) 1 (33.3) 2 (67)
(): % of the total number of patients analysed in each group.
aOR: 7; 95% CI: 2.4–20.7.
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specific for the promoter region of BRCA1, was performed with the
oligonucleotides in Table 2 (Esteller et al, 2000). Polymerase chain
reaction was performed using the HotMasterMix (Eppendorf AG,
Hamburg, Germany). Ten microliters of each PCR reaction were
directly loaded onto a 3% agarose gel, stained with ethidium
bromide and visualised under UV illumination. Samples were
scored positive only when a distinct band was present on the gel
and if BRCA1 hypermethylation was confirmed in two independent
experiments. The sensitivity of this MSP, obtained by diluting a
completely methylated sample into a nonmethylated sample, was
10% (data not shown).
Statistical analysis
Differences in BRCA1 expression levels between two sample
groups were analysed using the Mann–Whitney U Test. The
strength of the association between the expression levels of each
DNMT and BRCA1 according to the presence of BRCA1
hypermethylation was calculated by the Spearman rank-correla-
tion coefficient. The Fisher’s exact test was used to examine for
differences in patients’ characteristics according to BRCA1
hypermethylation. A multivariate analysis using the Cox regression
model was also performed. Odds ratios (OR) are given within 95%
confidence intervals (CI). All computations were performed using
the Stata 7.0 software (Stata Corp., College Station, TX, USA).
RESULTS
BRCA1 expression
We studied BRCA1 expression in normal haematopoietic cells and
AML samples by real-time PCR and by Western blot.
BRCA1 mRNA was expressed at barely detectable levels in
mature granulocytes, monocytes and lymphocytes separated from
normal PB (mean relative amount of BRCA1: 0.1970.07, vs
0.0370.01, vs 0.0870.02, respectively). In contrast, control BM-
MNCs and selected CD34þ progenitor cells expressed BRCA1
mRNA at high levels (mean relative amount of BRCA1: 32.377
and 52737, Figure 1).
In comparison to normal BM, BRCA1 expression level was
reduced in 56 AML samples (mean BRCA1 relative amount:
5.271.5, P¼0.0001, Figure 1).
The BRCA1 mRNA and protein were expressed at high levels by
TF1, HL60 and Raji cell lines (Figures 1 and 2, lanes 20–22).
BRCA1 protein expression in 19 AML samples was variable, and
consistently lower than that of cell lines (Figure 2, lanes 1–19).
Table 2 Oligonucleotide sequences
Gene Sequence Fragment length (bp) Reference or gene accession number
BRCA1-Unmet 50-TTGGTTTTTGTGGTAATGGAAAAGTGT
50-CAAAAAATCTCAACAAACTCACACCA
86 Esteller et al (2000)
BRCA1-Met 50-TCGTGGTAACGGAAAAGCGC
50-AAATCTCAACGAACTCACGCCG
76 Esteller et al (2000)
BRCA1-mRNA 50-ATGCTGAATGAGCATGATTTT
50-AGAGTGCTACACTGTCCAAC
352 Esteller et al (2000)
18S-mRNA 50-CGTTGATTAAGTCCCTGCCCTT
50-TCAAGTTCGACCGTCTTCTCAG
136 gi:337376
DNMT1-mRNA 50-GGTTCTTCCTCCTGGAGAATGTC
50-GGGCCACGCCGTACTG
141 gi:6684524
DNMT3A-mRNA 50-AGGAAGCGCAAGCACCC
50-ATTGGGTAATAGCTCTGAGGCG
114 gi:18033252
DNMT3B-mRNA 50-CCAGCCCTGCGGCAG
50-GTTGACGAGGATCGAGTCTTCC
93 gi:18033254
CCND2-mRNA 50-CGCTCACTTGTGATGCCCT
50-CTGCTCCTGGCAAGCTTTGAG
83 gi:16950656
P = 0.0003
P = 0.0001
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Figure 1 BRCA1 mRNA expression in AML and in normal blood cells.
Quantitative assessment of BRCA1 mRNA and the reference gene 18S
was performed using a fluorescence-based real-time detection method
(RT–PCR) and the dye SYBR Green. Arithmetic means are shown. Normal
BM and PB progenitor cells expressed high BRCA1 levels, when compared
to mature granulocytes, lymphocytes and monocytes (P¼0.0001). BRCA1
expression in AML was heterogeneous, similar to the haematopoietic cell
lines TF1, HL-60, KG1A, Jurkat and Raji, but lower than that of normal BM
(P¼0.0003).
BRCA1 hypermethylation in AML
A Scardocci et al
1110
British Journal of Cancer (2006) 95(8), 1108–1113 & 2006 Cancer Research UK
G
e
n
e
t
i
c
s
a
n
d
G
e
n
o
m
i
c
sBRCA1 hypermethylation
As promoter hypermethylation is a frequent event in malignant
diseases, leading to reduced tumour suppressor gene expression,
we then studied regulation of BRCA1 expression by promoter
hypermethylation in AML patients. DNA samples from 133 AML
patients were available, and 51 of them (38%) resulted hyper-
methylated. Fifteen BM and 25 PB samples from healthy
individuals resulted unmethylated. Figure 3 shows an example of
BRCA1 MSP.
Looking at the functional significance of BRCA1 hypermethyla-
tion, we found that methylation (n¼32 AML samples) correlated
to reduced BRCA1 expression, when compared to unmethylated
samples (n¼24, mean relative amount of BRCA1: 2.270.7 vs
9.273.4, P¼0.019, Figure 4A). Similarly, BRCA1 protein expres-
sion was reduced in methylated AML samples (Figure 2, lanes
2–13, and 16–18), when compared to unmethylated samples
(Figure 2, lanes 1, 14, 15 and 19).
We next analysed whether dysregulation of BRCA1 methylation
in AML could be correlated to DNA methyltransferases expression
levels. We studied 35 AML samples, 21 of them were hypermethy-
lated for BRCA1. DNMTs expression in AML samples correlated to
each other (DNMT1 and 3A: r¼0.71, Po0.0001; DNMT3A and 3B:
r¼0.52, P¼0.0013; DNMT1 and 3B: r¼0.35, P¼0.04). Median
expression of DNMT3A was higher in AML samples with
hypermethylated BRCA1 in comparison to unmethylated samples
(Figure 4B, P¼0.003), whereas expression levels of DNMT1 and 3B
did not differ according to BRCA1 methylation (P¼0.22 and 0.07,
respectively). There was a moderate negative correlation between
DNMT3A and BRCA1 expression (r¼ 0.35, P¼0.04).
When looking at patient characteristics associated to BRCA1
hypermethylation, the presence of chromosomal abnormalities was
associated to BRCA1 hypermethylation (P¼0.026, Table 1).
Furthermore, a significantly higher frequency of BRCA1
methylation was observed in patients with t-AML (16/21 t-AML,
75%, vs 32/112, 32%, P¼0.0002, OR 7 95% C.I. 2.4–20.7) (Table 1).
The Cox regression model showed that t-AML and karyotype were
independently associated to BRCA1 hypermethylation (P¼0.04
and 0.05, respectively).
DNA from the primary tumour sample was available for eight
patients with BRCA1 hypermethylation and t-AML. Three tumour
samples (three of four breast cancers) were hypermethylated for
BRCA-1, whereas in four patients hypermethylation was present in
the t-AML sample only.
Methylation
status − ++ ++ ++ +++++ + +++ −− − − − −
123 4567 89 1 0 1 11 21 3 1 6 1 7 1 8 14 15 19 22 21 20
BRCA1
β-Tubulin
Figure 2 BRCA1 protein expression. BRCA1 protein expression was studied by Western blot in 19 samples of patients with AML (lanes 1–19), and in
the TF-1, HL60 and Raji cell lines (lanes 20–22, respectively). Methylation status of the samples is indicated ( : unmethylated, þ: methylated for BRCA1).
C
U M UMUMUMUMUM M W
123 45
Figure 3 BRCA1 MS-PCR. Samples from patients 1, 2, 4 and 5 present
bands for both the unmethylated (U) and methylated (M) PCR-reactions,
whereas that from patient 3 is unmethylated. MW is the molecular weight
marker (100bp DNA ladder), whereas C is the negative control, containing
water instead of DNA, for ‘unmethylated’ and ‘methylated’ PCR reactions.
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Figure 4 BRCA1 mRNA expression according to methylation status. In
patients with AML and BRCA1 hypermethylation, a significant reduction of
BRCA1 expression was observed (A). On the other hand, hypermethyla-
tion was associated to high DNMT3A expression (B). The samples
analysed for each group are shown. — Indicates mean expression levels.
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sDISCUSSION
We studied expression of BRCA1, which plays a pivotal role in
DNA repair, particularly in response to DNA-damaging agents, in
AML and in normal haematopoiesis. We found that BRCA1 is
expressed at high levels in normal BM progenitor and in CD34þ
cells, whereas its expression is reduced in mature PB cells, such as
granulocytes, monocytes and lymphocytes. The variable BRCA1
expression may be related to different proliferation rates in the
mature compartment when compared to progenitor cells, but also
point to a functional role of BRCA1 during the early phases of
haematopoiesis, to maintain genomic integrity.
There are only few data on BRCA1 expression in haematologic
malignancies. In chronic myeloid leukaemia, it has been shown
that expression of the p210 BCR-ABL fusion protein leads to a
downregulation of BRCA1 protein expression, owing to post-
transcriptional mechanisms (Deutsch et al, 2003). In AML
samples, we found heterogeneous BRCA1 expression. As leukae-
mias are among malignancies with the highest methylation density
(Melki et al, 1999; Costello et al, 2000), we studied regulation of
BRCA1 expression by promoter hypermethylation. Indeed, we
found that 32% of primary AML samples and 75% of t-AML are at
least partially hypermethylated at the BRCA1 locus. Hypermethy-
lation of BRCA1 correlated to reduced mRNA and protein
expression, when compared to unmethylated samples, and to high
levels of DNA-methyltransferases 3A. High DNMT expression in
AML has been reported also by other authors, and is the basis for
new therapeutic approaches using demethylating agents (Mizuno
et al, 2001; Langer et al, 2005). In the same line, 60% of pancreatic
carcinomas were recently found to be hypermethylated at the
BRCA1 gene and the number of methylated genes significantly
correlated to DNMT1 protein overexpression (Peng et al, 2006).
BRCA1 hypermethylation has not been previously reported in
AML. Using a Southern blot technique, Bianco et al (2000) did not
find methylation of BRCA1 in 19 leukaemia samples, including 11
samples from patients with AML. Using MS-PCR, Esteller et al
(2001) reported no BRCA1 methylation in 19 leukaemia samples,
but did not specify the type of leukaemias studied. The different
results of our study could be due to the large number of patients
studied, including 21 patients with t-AML, and to the different
sensitivity of our MS-PCR. The frequency of BRCA1 methylation in
our AML patients is similar to that of patients with breast, ovarian
and pancreatic carcinomas. Other tumour types as colon cancer
and hepatocellular carcinomas did not show aberrant BRCA1
methylation (Bianco et al, 2000; Esteller et al, 2001). When
analysing primary tumour samples of patients with secondary
AML, we found BRCA1 hypermethylation only in breast cancer
samples. The number of samples analysed is small, but three of
four breast cancers showed BRCA1 hypermethylation, which might
indicate that in breast cancer complicated by a t-AML, the
frequency of BRCA1 hypermethylation is higher than the 11–31%
reported in the literature (Catteau and Morris, 2002). As patients
treated for breast cancer are at particular risk for t-AML, it will be
of interest to study whether BRCA1 hypermethylation can identify
the patients at increased risk for this complication. The loss of
BRCA1 function thus appears to be a double-edged sword: it may
increase sensitivity to chemotherapy commonly used in breast and
ovarian cancer and translate into favourable prognosis, but on the
other side, it may trigger secondary leukaemogenesis.
As primary tumours other than breast cancer in our series did
not show BRCA1 hypermethylation, this suggests a role of the
cytotoxic treatment in the induction of DNA hypermethylation in
t-AML. Accordingly, hypermethylation of several genes has been
reported in t-AML (Christiansen et al, 2003; Voso et al, 2004;
Larson and Le Beau, 2005), and ionising radiation has been shown
to induce hypermethylation.
None of the five cell lines we analysed were hypermethylated at
the BRCA1 locus and Esteller et al (2000) did not find any BRCA1
hypermethylation in 21 breast cancer cell lines. Reversibility of
methylation has been proposed to be an explanation for the rarity
of BRCA1 hypermethylation in cell lines, where restoration of gene
expression could confer a selective advantage during establishment
of cultures in vitro (Catteau and Morris, 2002).
BRCA1 is of particular importance as a regulator of chemo/
radiotherapy-induced damage: it accumulates in nuclear foci
during S-phase and reassembles into DNA repair-associated foci
after DNA damage. The loss of BRCA1 function results in the
accumulation of genomic alterations after exposure to DNA-
damaging agents. In the same line, we observed a higher frequency
of chromosomal translocations and other aberrations in AML
patients with BRCA1 hypermethylation. This association was
independent from the type of AML (de novo vs therapy-related).
The results of our study lead to the hypothesis that loss of
BRCA1 function could be a pathogenetic mechanism in t-AML.
Further experimental studies will have to examine the conse-
quences of reduced BRCA1 gene expression in AML on DNA
repair and genomic stability.
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